Does Cigna Cover Zepbound? Coverage Rules, Prior Authorization, and How to Appeal a Denial

What Is Zepbound and Why Does Coverage Matter?

Zepbound is tirzepatide, a once-weekly injectable medication approved by the FDA on November 8, 2023, for chronic weight management in adults with a body-mass index (BMI) of 30 or higher, or BMI of 27 or higher alongside at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia [1]. It works by activating both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. That dual-receptor mechanism separates it from semaglutide, which targets GLP-1 only.

The efficacy data are substantial. In SURMOUNT-1 (N=2,539), published in the New England Journal of Medicine, patients on 15 mg tirzepatide lost a mean 20.9% of body weight over 72 weeks compared with 3.1% on placebo (P<0.001) [2]. Patients on 10 mg lost 19.5% and patients on 5 mg lost 15.0% [2]. These are the largest weight-loss percentages ever recorded for a pharmaceutical agent in a phase 3 randomized trial for obesity without surgical intervention.

At a list price of roughly $1,059 per month, 72 weeks of treatment costs more than $19,000 out of pocket. That makes insurance status a practical clinical variable, not merely an administrative one. Cigna's commercial coverage policy is the most common insurance question our clinicians field for this drug.

Coverage determinations also carry a downstream health significance. Obesity affects more than 40% of U.S. adults and is linked to type 2 diabetes, cardiovascular disease, sleep apnea, and certain cancers [3]. The American Gastroenterological Association's 2022 clinical practice guidelines state: "Pharmacotherapy for obesity should be offered to all eligible patients as part of a comprehensive treatment plan that includes lifestyle intervention" [4]. Cigna's policies, when read carefully, align with these guidelines, but only if the prescribing physician provides the right documentation from the start.

Does Cigna Cover Zepbound for Weight Loss?

Most Cigna commercial health plans do cover Zepbound for chronic weight management, but coverage is never automatic. Every plan reviewed by the HealthRX benefits team required prior authorization. Cigna's medical policy for anti-obesity pharmacotherapy follows a benefit-design framework in which coverage is plan-specific, meaning an employer group may opt out of obesity drug benefits entirely.

Two scenarios exist. First, the employer's plan includes a pharmacy benefit that covers anti-obesity medications. In that case, Zepbound sits on the formulary, usually at Tier 3 or Tier 4, and is accessible via prior authorization. Second, the employer has carved out obesity pharmacotherapy from the formulary, which is legal under current federal law because obesity drugs are not mandated benefits for most commercial insurer products [5]. If the plan excludes obesity drugs as a class, no appeal will succeed on clinical grounds alone.

Before your provider submits a prior-authorization request, verify benefit inclusion by calling the member services number on your Cigna ID card or logging into myCigna.com and searching the formulary for "tirzepatide." If the drug does not appear at all, ask the plan administrator at your employer whether an obesity-drug rider is available during the next open enrollment period.

Cigna also distinguishes between the brand-name Zepbound and compounded tirzepatide. Compounded versions are not FDA-approved and Cigna does not cover them under standard pharmacy benefits [1]. During a period when FDA-listed shortages existed for tirzepatide (2023 to early 2025), some prescribers pivoted to compound pharmacies, but that pathway carries both regulatory and coverage risk [6].

Cigna Prior Authorization Criteria for Zepbound

Prior authorization for Zepbound on Cigna commercial plans generally requires documentation of four categories of clinical information.

BMI threshold. Most Cigna PA criteria require a documented BMI of 30 or a BMI of 27 with at least one weight-related comorbidity. Qualifying comorbidities typically include type 2 diabetes, hypertension (blood pressure 130/80 or higher on two readings), hyperlipidemia, obstructive sleep apnea confirmed by polysomnography, or nonalcoholic steatohepatitis [7].

Dietary and lifestyle counseling participation. Cigna commonly requires evidence that the patient is enrolled in, or has been referred to, a structured behavioral weight-loss program. The 2013 AHA/ACC/TOS guideline on the management of overweight and obesity recommends at least 14 sessions of behavioral intervention in the first 6 months [8]. Documenting referral to such a program before submission strengthens the PA.

Contraindication or failure of prior agents. Under step-therapy requirements (discussed in detail below), Cigna may require trial and inadequate response to orlistat, phentermine-topiramate, naltrexone-bupropion, or liraglutide 3 mg before Zepbound is approved. For patients who have already tried semaglutide 2.4 mg (Wegovy) and did not achieve adequate response, that trial counts as step therapy in most Cigna PA reviews.

Absence of contraindications. Zepbound carries a boxed warning for a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1]. Cigna PA forms ask the prescriber to confirm these are absent. The prescriber must also confirm the patient is not pregnant, as GLP-1/GIP agents are contraindicated in pregnancy.

Once submitted, Cigna has a statutory obligation to render a PA decision within 72 hours for urgent requests and 15 calendar days for standard requests under most state insurance codes. Keep a timestamp of your submission and follow up at 72 hours if no decision has been issued.

The HealthRX clinical team developed the following documentation checklist specifically for Zepbound PA submissions to Cigna. Providers who submit all seven elements in the initial packet reduce denial rates substantially compared with incomplete submissions.

1. Height, weight, and calculated BMI from a visit within 90 days.
2. ICD-10 code E66.01 (morbid obesity) or E66.09 (other obesity) plus any comorbidity codes.
3. Fasting lipid panel, HbA1c, and blood pressure from the same visit window.
4. Documentation of behavioral counseling referral or enrollment.
5. For step therapy: chart notes or pharmacy records showing prior anti-obesity drug trial with dates and doses.
6. Prescriber attestation that the patient has no personal or family history of medullary thyroid carcinoma or MEN2.
7. A brief clinical narrative (2, 4 sentences) explaining why prior agents were inadequate or contraindicated.

Step Therapy Requirements on Cigna Plans

Step therapy means the insurer requires patients to try and fail at least one less-expensive drug before the preferred agent is covered. Cigna applies step therapy to Zepbound on most commercial formularies.

The agents most commonly required as "Step 1" on Cigna plans include orlistat 120 mg three times daily with meals, phentermine-topiramate extended-release (Qsymia), and naltrexone-bupropion extended-release (Contrave). Some Cigna plan designs also place liraglutide 3 mg (Saxenda) as a required step before tirzepatide. A documented 12-week trial with either no weight loss or <5% body-weight reduction generally satisfies the step-therapy requirement for those agents [9].

Patients who have type 2 diabetes and are already on tirzepatide 5 mg, 10 mg, or 15 mg (Mounjaro) for glycemic control occupy a special position. Mounjaro and Zepbound share the same active ingredient at the same doses. Cigna does not typically count a Mounjaro prescription as Zepbound step therapy because the claim was submitted under a diabetes indication. Your provider may need to write a specific letter explaining the overlap and arguing that adding a second tirzepatide prescription under a different indication is redundant and clinically unnecessary.

The federal Restoring the Patient's Voice Act, introduced in Congress in 2023, would restrict insurers from imposing step therapy on FDA-approved obesity medications with demonstrated superiority data. That legislation has not yet passed as of this publication date, so step therapy remains a standard Cigna requirement [10].

What Tier Is Zepbound on the Cigna Formulary?

Formulary tier determines your copay or coinsurance rate. Cigna's commercial formularies vary by employer contract, but Zepbound most commonly lands at Tier 3 (preferred brand) or Tier 4 (non-preferred brand/specialty), depending on which other GLP-1 or GIP/GLP-1 agents have negotiated preferred status in a given plan year.

At Tier 3, a typical Cigna member pays a fixed copay of $50, $100 per 28-day supply after the deductible. At Tier 4, the member pays a percentage coinsurance, often 25 to 40% of the negotiated rate. On a $1,059 list price, 30% coinsurance equals roughly $318 per month before any manufacturer savings card is applied.

Cigna Express Scripts (ESI) is Cigna's pharmacy benefit manager. ESI's national preferred formulary as of the 2024 formulary year listed tirzepatide for weight management at Tier 4 with prior authorization [11]. Employers can negotiate different tier placement, so check your specific Summary of Benefits and Coverage document. The drug name to search is "tirzepatide" rather than "Zepbound," because PBM formulary databases often list by generic or active ingredient.

How to Appeal a Cigna Denial of Zepbound

Cigna uses a two-level internal appeal process followed by access to an external independent review organization (IRO). Missing a deadline at any level forfeits that appeal right.

Level 1 Internal Appeal. File within 180 days of the denial notice. Submit a written appeal letter, the prescriber's PA documentation, and any new clinical records not included in the original submission. Include peer-reviewed literature supporting Zepbound's clinical utility. Citing SURMOUNT-1's 20.9% weight loss finding at 72 weeks on 15 mg tirzepatide is appropriate and specific [2]. Cigna must respond within 60 days for standard appeals and 72 hours for expedited appeals where delay would harm health.

Level 2 Internal Appeal. If Level 1 is denied, file a Level 2 appeal within 60 days of that denial. This review is conducted by a Cigna medical director who was not involved in the Level 1 decision. A letter from your physician's specialist (endocrinologist or obesity medicine specialist) carries additional weight at this stage. The American Board of Obesity Medicine offers board certification specifically for this specialty; referencing your prescriber's credentials can help [12].

External Independent Review. After exhausting both internal levels, you can request review by a state-certified IRO. Under the Affordable Care Act, insurers must provide access to external review for coverage denials based on medical necessity [13]. The IRO reviewer is a board-certified physician with no financial relationship with Cigna. Published data from state insurance department annual reports show that external reviewers overturn insurer denials in approximately 39 to 45% of obesity drug cases, a higher reversal rate than the overall external review average of 26% [14].

State Insurance Department Complaint. File a parallel complaint with your state's department of insurance if Cigna misses statutory response deadlines or fails to follow its own appeals procedure. This does not cost anything and creates a documented record that may accelerate resolution.

Can I Use the Eli Lilly Savings Card with Cigna Coverage?

Eli Lilly offers a Zepbound savings card through its LillyDirect program. For commercially insured patients who are eligible, the card reduces out-of-pocket cost to as low as $25 per month for a 1-month prescription or $50 for a 3-month supply. The savings card cannot be used by patients enrolled in Medicare, Medicaid, or any other federal or state government-funded health program [1].

Cigna is a commercial insurer, so most Cigna members are eligible for the savings card. The key restriction is that the card can only be applied at participating retail pharmacies. When submitting the prescription, provide both the Cigna insurance information and the savings card. The pharmacy processes the Cigna claim first; any remaining balance is covered by the savings card up to the program limit.

One important caveat: some Cigna high-deductible health plans (HDHPs) paired with a health savings account (HSA) have terms that disallow manufacturer copay cards before the deductible is met. This is an IRS compliance issue specific to HSA-linked plans, not a Cigna policy restriction per se. Confirm with your plan whether the copay card applies pre-deductible.

If coverage is denied and you are paying cash, the LillyDirect self-pay vials program offers Zepbound single-dose vials at $349, $499 per month depending on the dose, which is substantially below the $1,059 pharmacy retail list price. This cash-pay pathway bypasses insurance entirely and does not require a savings card.

Cigna Coverage for Zepbound in Patients With Type 2 Diabetes

Tirzepatide holds a separate FDA approval as Mounjaro for type 2 diabetes, and the glycemic indication data are also strong. In the SURPASS-2 trial (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.46 percentage points compared with 1.86 points for semaglutide 1 mg (P<0.001), while also producing 12.4 kg greater weight loss [15]. The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists and dual GIP/GLP-1 agents with demonstrated cardiovascular or weight benefit as preferred add-on agents after metformin in patients with obesity and type 2 diabetes [16].

For Cigna members with type 2 diabetes, Mounjaro may face different prior-authorization criteria and formulary tier placement than Zepbound. The diabetes indication often results in lower copays and fewer step-therapy hurdles because type 2 diabetes is a mandatory-coverage condition under most benefit designs. Prescribers should consider whether submitting under the diabetes indication (E11.xx) is clinically appropriate and more likely to receive prompt authorization.

Patients approved for Mounjaro for diabetes who also have obesity should not be prescribed Zepbound as a duplicate claim for the same drug. The appropriate approach is to have the prescriber document both indications under the single Mounjaro prescription and ensure the chart reflects both the HbA1c management goal and the weight-management goal.

What to Do If Your Employer's Plan Excludes Obesity Drugs

Roughly 35 to 40% of employer-sponsored health plans in the United States still exclude obesity pharmacotherapy as a class benefit [17]. If Cigna confirms your plan excludes obesity drugs, your options include the following.

Request a formulary exception based on a distinct medical necessity argument. While this rarely succeeds when the exclusion is categorical, it creates documentation for an escalated employer complaint.

Speak directly with your human resources benefits manager. Employers have the ability to amend plan designs at open enrollment. Presenting data on reduced downstream healthcare costs from treated obesity can shift the business case. A 2022 analysis in Obesity estimated that pharmacologic treatment of obesity reduces 10-year cardiovascular event costs by $9,000, $14,000 per treated patient [18].

Use the LillyDirect cash-pay vials at $349, $499 per month as a bridge until plan design changes. Apply for Eli Lilly patient assistance programs if household income is at or below 400% of the federal poverty level.

Consider enrolling in a HealthRX-affiliated telehealth program that includes Zepbound prescribing, pharmacy fulfillment, and benefits navigation support as a single service.

Monitoring Requirements Cigna May Use to Continue Coverage

Cigna and most commercial insurers require periodic reassessment to continue Zepbound coverage beyond the initial authorization period, typically 3 to 6 months. Standard continuation criteria include documentation of at least 5% total body-weight reduction from baseline at 12 to 16 weeks on the medication [9]. The FDA label for Zepbound states that discontinuation should be considered in patients who do not achieve 5% weight loss after 16 weeks on the 10 mg or 15 mg maintenance dose [1].

This threshold aligns with the Endocrine Society's 2015 pharmacological management guideline, which states: "If a patient does not lose at least 5 percent of baseline body weight after 12 weeks of treatment with the highest tolerated dose, the medication should be discontinued" [19]. Having your provider document weight at every visit and submit updated weights with renewal PA requests reduces the risk of a continuity-of-therapy denial.

Blood pressure, fasting glucose or HbA1c, and lipid panel results from follow-up visits also strengthen renewal submissions by demonstrating cardiometabolic benefit beyond weight alone.